RCEL
Price
$9.21
Change
+$0.19 (+2.11%)
Updated
Apr 17 closing price
Capitalization
399.48M
18 days until earnings call
STXS
Price
$1.85
Change
+$0.06 (+3.35%)
Updated
Apr 17 closing price
Capitalization
214.36M
23 days until earnings call
Ad is loading...

RCEL vs STXS

Header iconRCEL vs STXS Comparison
Open Charts RCEL vs STXSBanner chart's image
Avita Medical
Price$9.21
Change+$0.19 (+2.11%)
Volume$133.33K
Capitalization399.48M
Stereotaxis
Price$1.85
Change+$0.06 (+3.35%)
Volume$252.21K
Capitalization214.36M
RCEL vs STXS Comparison Chart
Loading...
RCEL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
STXS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
RCEL vs. STXS commentary
Apr 20, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is RCEL is a Hold and STXS is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 20, 2025
Stock price -- (RCEL: $9.21 vs. STXS: $1.85)
Brand notoriety: RCEL and STXS are both not notable
Both companies represent the Medical Specialties industry
Current volume relative to the 65-day Moving Average: RCEL: 60% vs. STXS: 43%
Market capitalization -- RCEL: $399.48M vs. STXS: $214.36M
RCEL [@Medical Specialties] is valued at $399.48M. STXS’s [@Medical Specialties] market capitalization is $214.36M. The market cap for tickers in the [@Medical Specialties] industry ranges from $3.82T to $0. The average market capitalization across the [@Medical Specialties] industry is $8.37B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

RCEL’s FA Score shows that 0 FA rating(s) are green whileSTXS’s FA Score has 0 green FA rating(s).

  • RCEL’s FA Score: 0 green, 5 red.
  • STXS’s FA Score: 0 green, 5 red.
According to our system of comparison, RCEL is a better buy in the long-term than STXS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

RCEL’s TA Score shows that 5 TA indicator(s) are bullish while STXS’s TA Score has 3 bullish TA indicator(s).

  • RCEL’s TA Score: 5 bullish, 4 bearish.
  • STXS’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, RCEL is a better buy in the short-term than STXS.

Price Growth

RCEL (@Medical Specialties) experienced а +6.72% price change this week, while STXS (@Medical Specialties) price change was +11.45% for the same time period.

The average weekly price growth across all stocks in the @Medical Specialties industry was +1.65%. For the same industry, the average monthly price growth was -9.67%, and the average quarterly price growth was -5.07%.

Reported Earning Dates

RCEL is expected to report earnings on Aug 07, 2025.

STXS is expected to report earnings on Aug 07, 2025.

Industries' Descriptions

@Medical Specialties (+1.65% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RCEL($399M) has a higher market cap than STXS($214M). STXS YTD gains are higher at: -18.860 vs. RCEL (-28.047). STXS has higher annual earnings (EBITDA): -21.24M vs. RCEL (-33.54M). RCEL has more cash in the bank: 89.1M vs. STXS (19.8M). STXS has less debt than RCEL: STXS (5.49M) vs RCEL (42.4M). RCEL has higher revenues than STXS: RCEL (50.1M) vs STXS (26.8M).
RCELSTXSRCEL / STXS
Capitalization399M214M186%
EBITDA-33.54M-21.24M158%
Gain YTD-28.047-18.860149%
P/E RatioN/AN/A-
Revenue50.1M26.8M187%
Total Cash89.1M19.8M450%
Total Debt42.4M5.49M772%
FUNDAMENTALS RATINGS
RCEL vs STXS: Fundamental Ratings
RCEL
STXS
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
65
Fair valued
92
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
5372
P/E GROWTH RATING
1..100
10052
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

RCEL's Valuation (65) in the null industry is in the same range as STXS (92) in the Medical Specialties industry. This means that RCEL’s stock grew similarly to STXS’s over the last 12 months.

RCEL's Profit vs Risk Rating (100) in the null industry is in the same range as STXS (100) in the Medical Specialties industry. This means that RCEL’s stock grew similarly to STXS’s over the last 12 months.

RCEL's SMR Rating (100) in the null industry is in the same range as STXS (100) in the Medical Specialties industry. This means that RCEL’s stock grew similarly to STXS’s over the last 12 months.

RCEL's Price Growth Rating (53) in the null industry is in the same range as STXS (72) in the Medical Specialties industry. This means that RCEL’s stock grew similarly to STXS’s over the last 12 months.

STXS's P/E Growth Rating (52) in the Medical Specialties industry is somewhat better than the same rating for RCEL (100) in the null industry. This means that STXS’s stock grew somewhat faster than RCEL’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
RCELSTXS
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bearish Trend 4 days ago
84%
Bearish Trend 4 days ago
82%
Momentum
ODDS (%)
Bullish Trend 4 days ago
76%
Bullish Trend 4 days ago
89%
MACD
ODDS (%)
Bullish Trend 4 days ago
87%
Bullish Trend 4 days ago
83%
TrendWeek
ODDS (%)
Bullish Trend 4 days ago
76%
Bullish Trend 4 days ago
82%
TrendMonth
ODDS (%)
Bearish Trend 4 days ago
85%
Bullish Trend 4 days ago
81%
Advances
ODDS (%)
Bullish Trend 6 days ago
74%
Bullish Trend 4 days ago
76%
Declines
ODDS (%)
Bearish Trend 10 days ago
79%
Bearish Trend 17 days ago
82%
BollingerBands
ODDS (%)
Bullish Trend 4 days ago
76%
Bearish Trend 4 days ago
90%
Aroon
ODDS (%)
Bearish Trend 4 days ago
82%
Bearish Trend 4 days ago
88%
View a ticker or compare two or three
Ad is loading...
RCEL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
STXS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
GME26.780.53
+2.02%
GameStop Corp
AAPL196.982.71
+1.39%
Apple
BTC.X85063.414000612.609400
+0.73%
Bitcoin cryptocurrency
SPY525.66N/A
N/A
SPDR® S&P 500® ETF
TSLA241.37-0.18
-0.07%
Tesla

RCEL and

Correlation & Price change

A.I.dvisor indicates that over the last year, RCEL has been loosely correlated with PHCCF. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if RCEL jumps, then PHCCF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RCEL
1D Price
Change %
RCEL100%
+2.11%
PHCCF - RCEL
42%
Loosely correlated
N/A
INMD - RCEL
36%
Loosely correlated
+0.07%
BLFS - RCEL
35%
Loosely correlated
-1.57%
MBOT - RCEL
34%
Loosely correlated
+1.22%
STXS - RCEL
33%
Poorly correlated
+3.35%
More

STXS and

Correlation & Price change

A.I.dvisor indicates that over the last year, STXS has been loosely correlated with SMTI. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if STXS jumps, then SMTI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To STXS
1D Price
Change %
STXS100%
+3.35%
SMTI - STXS
37%
Loosely correlated
+2.58%
RGEN - STXS
36%
Loosely correlated
-1.59%
PRCT - STXS
35%
Loosely correlated
+0.42%
ICUI - STXS
34%
Loosely correlated
-0.34%
TWST - STXS
34%
Loosely correlated
-4.29%
More